Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2016-10-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/ACSMEDCHEMLETT.6B00314PMID 27994747PMCID PMC5150677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.

  2016cited by this paper
• GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling

  2016cited by this paper
• Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

  2015cited by this paper
• Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.

  2013cited by this paper
• Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

  2013cited by this paper
• Triazoloamides as potent γ-secretase modulators with reduced hERG liability.

  2012cited by this paper
• Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.

  2012cited by this paper
• Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.

  2012cited by this paper
• Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2009cited by this paper
• Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure

  2009cited by this paper
• Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

  2008cited by this paper
• Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

  2008cited by this paper
• When poor solubility becomes an issue: from early stage to proof of concept.

  2007cited by this paper
• Characterisation and differential expression of two very closely related G-protein-coupled receptors, GPR139 and GPR142, in mouse tissue and during mouse development.

  2006cited by this paper
• Diabetes mellitus: pathogenesis and treatment strategies.

  2004cited by this paper
• Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.

  2004cited by this paper
• Estimation of the aqueous solubility I: application to organic nonelectrolytes.

  2001cited by this paper
• Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas

  1967cited by this paper
• TREATMENT OF DIABETES.

  1923cited by this paper

• Tryptophan‐sensing receptor GPR142 expression levels are directly regulated by proinflammatory cytokines in ghrelin‐producing cells

  2025cites this paper
• Genome-Wide Linkage and Association of Novel Genes and Pathways with Type 2 Diabetes in Italian Families

  2024cites this paper
• The Application of High‐Throughput Approaches in Identifying Novel Therapeutic Targets and Agents to Treat Diabetes

  2022cites this paper
• Aqueous Ethanolic Extract of Adiantum incisum Forssk. Protects against Type 2 Diabetes Mellitus via Attenuation of α-Amylase and Oxidative Stress

  2022cites this paper
• An extensive research on aldose reductase inhibitory effects of new 4H-1,2,4-triazole derivatives

  2021cites this paper
• Synthesis and antidiabetic activity of novel triazole derivatives containing amino acids

  2020cites this paper
• Leveraging the Gut to Treat Metabolic Disease.

  2020cites this paper
• Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.

  2019cites this paper
• Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.

  2018cites this paper
• G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

  2018influential citation
• GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function

  2018cites this paper
• The GPR139 reference agonists 1a and 7c, and tryptophan and phenylalanine share a common binding site

  2017cites this paper
• Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II

  2017cites this paper
• Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I

  2017cites this paper
• Copper (II) Ions Immobilized onto Aminoquinoline‐Functionalized Ferrite: A New Efficient and Recoverable Catalyst for “in Water” Synthesis of Triazole Derivatives

  2017cites this paper